Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 12, 2001, Pages 2026-2031

  Stein, Daniel T ^a   Devaraj, Sridevi ^a   Balis, David ^a   Adams Huet, Beverley ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Non HDL cholesterol; Remnants; Statins

Indexed keywords

ATORVASTATIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035569936     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq1201.100259     Document Type: Article

References (47)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
2. Randomized trial of cholesterol lowering in 4444 patients with CAD: Scandinavian Simvastatin Survival Study (4S)
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention study
6. Current perspectives on statins
7. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
8. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins
9. TG-rich lipoproteins and atherosclerosis: New perspectives
10. Atherogenicity of TG-rich lipoproteins
11. Postprandial lipoproteins and progression of CAD
12. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis
13. Postprandial lipoprotein metabolism and atherosclerosis
14. IDL and progression of carotid atherosclerosis
15. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease
16. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
17. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels
18. RLP-cholesterol levels in patients with dysbetalipoproteinemia and CAD
19. Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease
20. Remnant-like particles and restenosis of coronary arteries after PTCA
21. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death
22. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels
23. High postprandial plasma remnant-like particles-cholesterol in patients with coronary artery diseases on chronic maintenance hemodialysis
24. Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis
25. An increase of serum remnant-like particles in non-insulin-dependent diabetic patients with microalbuminuria
26. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
27. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study)
28. Comparison of an immunoprecipitation method for direct measurement of LDL-cholesterol with beta-quantification (ultracentrifugation)
29. Comparison of two assays for measuring LDL cholesterol
30. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart study
31. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
32. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men
33. Effect of fluvastatin on IDL (remnants) and other lipoprotein levels in hypercholesterolemia
34. Pravastatin therapy in primary moderate hypercholesterolemia
35. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia
36. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia
37. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia
38. Comparison of statins in hypertriglyceridemia
39. RLP cholesterol concentration and progression of coronary and vein graft atherosclerosis in response to gemfibrozil treatment
40. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
41. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
42. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: Relationships between apolipoprotein B kinetics and plasma lipoproteins
43. Physiologic mechanisms of action of lovastatin in nephrotic syndrome
44. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects
45. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin
46. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia: Collaborative Atorvastatin Study Group
47. HMG-CoA reductase inhibitors and hepatic apo B secretion